Robert E. Hoffman
CIK 1166288 · Chief Executive Officer · last filed 2026-10-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6166 NANCY RIDER DRIVE
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. (ESPR) Delisted | Director | 0 | $3.18 | $0 | $0 | 4 | 2026-07-13 |
| FBLG | Director | — | $0.93 | — | $0 | 3 | 2026-06-23 |
| HURA | Director | — | $2.03 | — | $0 | 2 | 2026-02-17 |
| TuHURA Biosciences, Inc./NV (KTRA) Delisted | President, CEO and Interim CFO | 1,969 | $7.54 | $14.8K | $25.8K | 7 | 2023-09-01 |
| KURA | Director | — | $9.72 | — | $0 | 6 | 2021-06-23 |
| TuHURA Biosciences, Inc./NV (DMPI) Delisted | Director | — | — | — | $0 | 5 | 2020-06-30 |
| HRTX | CFO & SVP, Finance | 1,280 | $0.32 | $405 | -$1.15M | 5 | 2019-12-23 |
| Aravive, Inc. (ARAV) Delisted | Director | — | $0.04 | — | $0 | 3 | 2019-09-13 |
| CombiMatrix Corp (CBMX) Delisted | Director | 0 | — | — | $16.0K | 7 | 2017-11-16 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Director | 1,479 | — | — | $0 | 4 | 2017-05-23 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | SVP, Finance and CFO | 5,807 | $99.99 | $580.6K | -$1.17M | 16 | 2014-12-17 |
Recent Filings · Page 7 of 8
72 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-10-02 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Mixed | — | -$342.0K | EDGAR |
| 2012-07-09 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Sell (S) | −10,000 | -$110.0K | EDGAR |
| 2012-03-19 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-01-10 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Other (J) | — | $1 | EDGAR |
| 2011-09-15 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-03-18 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-03-18 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-09-02 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Sell (S) | −10,000 | -$61.6K | EDGAR |
| 2008-03-05 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-02-15 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Gift (G) | −700 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.